The end of the line is looming for Oxurion, after a clinical trial of its last pipeline drug for diabetic macular oedema (DME) failed to meet its primary endpoint.
Oxurion will carry out an interim analysis of a phase 2 trial of its last remaining clinical asset – THR-149 for diabetic macular oedema (DME) – before the end of this year as it tries to g
Shares in Belgian biotech Oxurion are taking a hammering this morning after it reported that one of its drugs for diabetic eye disease had failed a phase 2 trial and will be terminated.